

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cevazuril 50 mg/ml, oral suspension for piglets and calves.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Toltrazuril 50.0 mg

Excipients:

<u>Qualitative composition of excipients and other constituents</u>	<u>Quantitative composition if that information is essential for proper administration of the veterinary medicinal product</u>
Sodium propionate (E281)	2.1 mg
Sodium benzoate (E211)	2.1 mg
Docusate sodium	
Aluminium magnesium silicate	
Xanthan gum	
Propylene glycol	
Citric acid monohydrate	
Simeticone emulsion (containing sorbic acid)	
Water purified	

White homogeneous suspension.

3. CLINICAL INFORMATION

3.1 Target species

Pigs (Piglets 3 - 5 days old).
Cattle (calves on dairy farms).

3.2 Indications for use for each target species

I Piglets:

II For the prevention of clinical signs of coccidiosis in neonatal piglets on farms with a confirmed history of coccidiosis caused by *Isospora suis*.

Calves:

For the prevention of clinical signs of coccidiosis and reduction of coccidia shedding in housed calves replacing cows producing milk for human consumption (dairy cows) on farms with a confirmed history of coccidiosis, caused by *Eimeria bovis* or *Eimeria zuernii*.

3.3 Contraindications

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Cattle (for environmental reasons):

Do not use in calves weighing more than 80 kg bodyweight.

Do not use in fattening units such as veal or beef calves.

For more details, see section 3.5, special precautions for the protection of the environment and section 4, Environmental properties.

3.4 Special warnings

As with any antiparasiticide, frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance.

It is recommended to treat all piglets in a litter and all calves in a pen.

Hygienic measures may reduce the risk of porcine and bovine coccidiosis. It is therefore, recommended to improve concomitantly the hygienic conditions in the concerned facility, particularly dryness and cleanliness.

To alter the course of an established clinical coccidial infection in individual animals already showing signs of diarrhoea, additional supportive therapy may be required.

To obtain maximum benefit, animals should be treated before the expected onset of clinical signs, i.e. in the prepatent period.

3.5 Special precautions

Special precautions for safe use in the target species

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash any splashes from skin or eyes immediately with water.

Wash hands after veterinary medicinal product administration.

People with known hypersensitivity to any of the ingredients should avoid contact with the veterinary medicinal product.

Special precautions for the protection of the environment:

The major metabolite of toltrazuril, toltrazuril sulfone (ponazuril), has been shown to be both persistent (half-life > 1 year) and mobile in soil and to be toxic to plants.

In order to prevent any adverse effects on plants and possible contamination of groundwater, manure from treated calves must not be spread onto land without dilution with manure from toltrazuril untreated cattle. Manure from treated calves must be diluted with at least 3 times the weight of manure from toltrazuril untreated cattle before it can be spread onto land.

3.6 Adverse events

Cattle, pigs:

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to

either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Not applicable.

3.8 Interaction with other medicinal products and other forms of interaction

None known.

There is no interaction in combination with iron supplementation.

3.9 Administration routes and dosage

Oral use.

Shake well before use.

Piglets:

Individual animal treatment.

Each piglet to be treated on day 3-5 of life with a single oral dose of 20 mg toltrazuril/kg body weight corresponding to 0.4 ml oral suspension per kg body weight.

Treatment during an outbreak will be of limited value for the individual piglet because of damage to the small intestine having already occurred.

Due to the small volumes required to treat individual piglets, use of dosing equipment with a dose accuracy of 0.1 ml is recommended.

Calves:

Each calf should be treated with a single oral dose of 15 mg toltrazuril/kg body weight corresponding to 3 ml oral suspension per 10 kg body weight.

III For the treatment of a group of animals of the same breed and same or similar age, the dosing should be done according to the heaviest animal of this group.

To ensure a correct dosage, body weight should be determined as accurately as possible

IV

V 310 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

A threefold overdose is well tolerated without adverse clinical signs.

3.11. Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.11 Withdrawal periods

Meat and offal:

Pigs (piglets): 77 days.

Cattle (calves): 63 days.

VI Not authorised for use in animals producing milk for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QP51BC01

4.2 Pharmacodynamics

Toltrazuril is a triazinon derivative. It acts against coccidia of the genus *Isospora* and *Eimeria*. It is acting against all intracellular development stages of coccidia: merogony (asexual multiplication) and gamogony (sexual phase). All stages are destroyed, thus the mode of action is coccidiocidal.

4.3 Pharmacokinetics

Piglets:

VII After oral administration, toltrazuril is slowly absorbed with a bioavailability of 70%.

VIII The maximum concentration (C_{max}) of toltrazuril is of 8.9 mg/L and is obtained after around 24 h. The main metabolite is characterised as toltrazuril sulfone. The elimination of toltrazuril is slow with a terminal half-life elimination time around 76 hours. The major route of excretion is via the faeces.

Calves:

After oral administration toltrazuril is slowly absorbed.

The maximum concentration (C_{max}) toltrazuril is of 36.3 mg/L and is obtained after around 36 h.

The main metabolite is characterised as toltrazuril sulfone. The elimination of toltrazuril is slow with a terminal half-life time of around 96.4 hours. The major route of excretion is via the faeces.

Environmental properties

The metabolite of toltrazuril, toltrazuril sulfone (ponazuril) is a persistent (half-life > 1 year) and mobile compound and has adverse effects on both the growth and emergence of plants. Given the persistent properties of ponazuril repeated spreading of manure from treated animals may lead to an accumulation in the soil and consequently a risk to plants. The accumulation of ponazuril in soil together with its mobility also leads to a risk of leaching to groundwater. See sections 3.3 and 3.5.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf-life after first opening the immediate packaging: 6 months.

5.3. Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

5.4 Nature and composition of immediate packaging

Nature of immediate packaging:

High density polyethylene bottle

Polyethylene tamper evident screw cap with a polyethylene seal (100 ml and 250 ml bottle)

Polypropylene tamper evident screw cap with a polyethylene seal (1 L bottle)

Pack size

Cardboard box of 1 bottle of 100 ml

Cardboard box of 1 bottle of 250 ml

1-litre bottle

250 ml bottle.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Animal Health Ltd

7. MARKETING AUTHORISATION NUMBER(S)

Vm 15052/3040

8. DATE OF FIRST AUTHORISATION

25 June 2010

9. DATE OF THE LAST REVISION OF THE SUMMARY OF PRODUCT CHARACTERISTICS

September 2024

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

Revised December 2024
AN: 03537/2023

Gavin Hall

Approved 22 December 2024